RETENTION RATES OF ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB AS BIOTHERAPIES FOR RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, OR PSORIATIC ARTHRITIS PATIENTS IN DAILY PRACTICE IN AUVERGNE (FRANCE)

被引：0
|
作者：
Soubrier, M. [1 ]
Fan, A. [1 ]
Couderc, M. [1 ]
Malochet-Guinamand, S. [1 ]
Mathieu, S. [1 ]
Giraud, C. [1 ]
Tournadre, A. [1 ]
Dubost, J. -J. [1 ]
Pereira, B. [2 ]
机构：
[1] CHU Clermont Ferrand, Dept Rheumatol, Clermont Ferrand, France
[2] CHU Clermont Ferrand, Biostat Unit, Clermont Ferrand, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.5086
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB1333
引用
收藏
页码：1756 / 1756
页数：1
相关论文
共 50 条
  • [31] Predictors for terminating therapy of etanercept and infliximab in psoriatic arthritis patients
    Kristensen, L. E.
    Nilsson, J.
    Jacobsson, L. T. H.
    Saxne, T.
    Compagno, M.
    Geborek, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 222 - 222
  • [32] BIOLOGICAL DRUGS SURVIVAL IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND SPONDYLOARTHRITIS
    Marcos, Josefina
    Pablo Salas, Adrian
    Carolina Costi, Ana
    Sansinanea, Pierina
    Alejandra Pera, Mariana
    Aguila Maldonado, Rodrigo
    Argentina Garcia, Mercedes
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2016, 22 (03) : 128 - 128
  • [33] Psoriatic arthritis patients doing better on infliximab than etanercept
    Smith, N.
    Gadsby, K.
    Deighton, C.
    RHEUMATOLOGY, 2007, 46 (04) : 721 - 722
  • [34] Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis
    Fenix-Caballero, S.
    Alegre-del Rey, E. J.
    Castano-Lara, R.
    Puigventos-Latorre, F.
    Borrero-Rubio, J. M.
    Lopez-Vallejo, J. F.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2013, 38 (04) : 286 - 293
  • [35] Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis
    Pombo-Suarez, Manuel
    Seoane-Mato, Daniel
    Diaz-Gonzalez, Federico
    Cea-Calvo, Luis
    Sanchez-Alonso, Fernando
    Sanchez-Jareno, Marta
    Jovani, Vega
    Garcia-Magallon, Blanca
    Martinez-Gonzalez, Olga
    Campos-Fernandez, Cristina
    Manero, Javier
    Diaz-Torne, Cesar
    Bohorquez, Cristina
    Ros-Vilamajo, Inmaculada
    Perez-Vera, Yanira
    Castrejon, Isabel
    MUSCULOSKELETAL CARE, 2023, 21 (01) : 189 - 197
  • [36] OBESITY RATES AND BMI ARE SIMILAR IN AGE AND SEX MATCHED RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND SPONDYLOARTHRITIS PATIENTS
    Yardimci, G. K.
    Farisogullari, B.
    Bolek, E. C.
    Bilgin, E.
    Duran, E.
    Ayan, G.
    Ozsoy, Z.
    Uzun, G. Sandal
    Kilic, L.
    Akdogan, A.
    Karadag, O.
    Bilgen, S. A.
    Kiraz, S.
    Kalyoncu, U.
    Ertenli, A. I.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 518 - 519
  • [37] Comparative Disease Burden of Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Data from the Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
    Mease, Philip J.
    Liu, Mei
    Rebello, Sabrina
    Kang, Hyungjoo
    Park, Yujin
    Greenberg, Jeffrey
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [38] Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab
    María M. Katsicas
    Ricardo A. G. Russo
    Clinical Rheumatology, 2009, 28 : 985 - 988
  • [39] Efficacy and safety of adalimumab (HUMIRA®) in 899 patients with rheumatoid arthritis (RA) who previously failed etanercept and/or infliximab in clinical practice
    Bombardieri, S.
    McKenna, F.
    Drosos, A. A.
    Michel, B. A.
    Hartz, D.
    Oezer, U.
    Kupper, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 178 - 178
  • [40] Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and infliximab
    Katsicas, M. M.
    Russo, R. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 551 - 552
12345